Ibrance
palbociclib
- Strength
- 75 mg/1
- Form
- Capsule
- Class
- Kinase Inhibitor
Pfizer Laboratories Div Pfizer Inc
palbociclib
Listed by Pfizer Laboratories Div Pfizer Inc
| Dosage form | Capsule |
|---|---|
| Route | Oral |
| Drug class | Kinase Inhibitor |
| Approval route | NDA — original brand approval |
| NDC code | 0069-0188 |
| FDA application | NDA207103 |
| RxNorm concept | 1601380 |
| Package sizes listed | 1 |
| Marketed since | February 2015 |
Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
palbociclib
Pfizer Laboratories Div Pfizer Inc
palbociclib
U.S. Pharmaceuticals
palbociclib
U.S. Pharmaceuticals
palbociclib
U.S. Pharmaceuticals
palbociclib
Pfizer Laboratories Div Pfizer Inc
palbociclib
Pfizer Laboratories Div Pfizer Inc
palbociclib
Pfizer Laboratories Div Pfizer Inc
palbociclib
Pfizer Laboratories Div Pfizer Inc
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.
Please don't share card details in chat.